Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Prostate Cancer
Obesity drug inhibits prostate tumor growth
April 6th, 2004
The Burnham Institute's Jeffrey Smith, PhD, has discovered that orlistat, commonly prescribed as an antiobesity drug, has a positive side effect: It inhibits cancer growth. Smith made this discovery using an activity-based proteomics screening technique developed in his laboratory that makes it possible to identify active targets and simultaneously screen for their inhibitors. These results were published in the journal Cancer Research. The metabolism of a tumor cell is different from its normal counterpart cell. Scientists have long suspected that metabolism is connected to tumor progression. Smith and coworkers designed a proteomics screen...
Source: Cancer Weekly (2004-04-06)
|
